CD19 Redirected Autologous T Cells for Hodgkin Lymphoma

Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis Clinical Trial

Official title: Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCRζ and 4-1BB Signaling Domains in Patients With Chemotherapy Relapsed or Refractory Hodgkin Lymphoma

Status Terminated

Clinical Trial Summary

Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19) in Hodgkin Lymphoma (HL) patients.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Hodgkin Disease
• Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis
• Lymphoma

• NCT number: NCT02277522
• Study type: Interventional
• Source: University of Pennsylvania
• Status: Terminated
• Phase: Early Phase 1
• Start date: October 2014
• Completion date: June 27, 2017